EMA Authorised: Zercepac (trastuzumab) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised Zercepac, a trastuzumab biosimilar from Accord Healthcare S.L.U., for breast cancer and stomach cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Stomach Cancer

Drugs mentioned

• Zercepac (trastuzumab)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Stomach Neoplasms. MAH: Accord Healthcare S.L.U.. Decision date: 19/01/2026